Critical Survey: Oncology Institute (NASDAQ:TOI) & Pono Capital Two (NASDAQ:PTWO)

Oncology Institute (NASDAQ:TOI) and Pono Capital Two (NASDAQ:PTWO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Institutional & Insider Ownership

36.9% of Oncology Institute shares are held by institutional investors. Comparatively, 60.8% of Pono Capital Two shares are held by institutional investors. 13.1% of Oncology Institute shares are held by company insiders. Comparatively, 63.9% of Pono Capital Two shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Oncology Institute has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Pono Capital Two has a beta of 0.11, suggesting that its stock price is 89% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Oncology Institute and Pono Capital Two, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	0	0	1	0	3.00
Pono Capital Two	0	0	0	0	N/A

Oncology Institute currently has a consensus price target of $2.25, indicating a potential upside of 90.68%. Given Oncology Institute’s higher possible upside, equities research analysts plainly believe Oncology Institute is more favorable than Pono Capital Two.

Earnings and Valuation

This table compares Oncology Institute and Pono Capital Two’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$324.24 million	0.27	-$83.07 million	($0.92)	-1.28
Pono Capital Two	N/A	N/A	$340,000.00	N/A	N/A

Pono Capital Two has lower revenue, but higher earnings than Oncology Institute.

Profitability

This table compares Oncology Institute and Pono Capital Two’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-24.56%	-80.46%	-28.14%
Pono Capital Two	N/A	-6.63%	0.73%

Summary

Pono Capital Two beats Oncology Institute on 6 of the 10 factors compared between the two stocks.

About Oncology Institute

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.

About Pono Capital Two

Pono Capital Two, Inc. does not have any significant operations. It focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Pono Capital Two, Inc. was incorporated in 2022 and is based in Honolulu, Hawaii.